155 related articles for article (PubMed ID: 10906417)
21. Genetic toxicology of tricyclic carboxamides, a new class of DNA binding antitumour agent.
Ferguson LR; Hill CM; Baguley BC
Eur J Cancer; 1990; 26(6):709-14. PubMed ID: 2144158
[TBL] [Abstract][Full Text] [Related]
22. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
23. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
24. Genetic damage, but limited evidence of oxidative stress markers in diethyl maleate-induced glutathione depleted mouse lymphoma L5178Y (TK(+/-)) cell cultures.
Geter DR; Zhang F; Schisler MR; Wood AJ; Kan HL; Jeong YC; Bartels MJ; McFadden L; Gollapudi BB
Toxicol Mech Methods; 2012 Sep; 22(7):547-54. PubMed ID: 22564015
[TBL] [Abstract][Full Text] [Related]
25. Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Yamazaki H; Dilworth A; Myers CE; Sinha BK
Prostate; 1993; 23(1):25-36. PubMed ID: 8393191
[TBL] [Abstract][Full Text] [Related]
26. Mutagenicity of m-AMSA and o-AMSA in mammalian cells due to clastogenic mechanism: possible role of topoisomerase.
DeMarini DM; Doerr CL; Meyer MK; Brock KH; Hozier J; Moore MM
Mutagenesis; 1987 Sep; 2(5):349-55. PubMed ID: 2830452
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the genotoxicity of anthraquinones in mammalian cells.
Mueller SO; Stopper H
Biochim Biophys Acta; 1999 Aug; 1428(2-3):406-14. PubMed ID: 10434060
[TBL] [Abstract][Full Text] [Related]
28. A comparative study of genotoxic effects of anti-topoisomerase II drugs ICRF-193 and bufalin in Chinese hamster ovary cells.
Pastor N; Domínguez I; Mateos S; Cortés F
Mutat Res; 2002 Mar; 515(1-2):171-80. PubMed ID: 11909765
[TBL] [Abstract][Full Text] [Related]
29. Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells.
Snyder RD
Environ Mol Mutagen; 2000; 35(1):13-21. PubMed ID: 10692223
[TBL] [Abstract][Full Text] [Related]
30. Using yeast to study resistance to topoisomerase II-targeting drugs.
Nitiss JL
Cancer Chemother Pharmacol; 1994; 34 Suppl():S6-13. PubMed ID: 8070029
[TBL] [Abstract][Full Text] [Related]
31. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
32. Sister-chromatid exchanges (SCE) induction by inhibitors of DNA topoisomerases in cultured human lymphocytes.
Ribas G; Xamena N; Creus A; Marcos R
Mutat Res; 1996 Jul; 368(3-4):205-11. PubMed ID: 8692226
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.
Cummings J; Sumner AT; Slavotinek A; Meikle I; Macpherson JS; Smyth JF
Mutat Res; 1995 Aug; 344(1-2):55-62. PubMed ID: 7565893
[TBL] [Abstract][Full Text] [Related]
34. Differentiated and exponentially growing HL60 cells exhibit different sensitivity to some genotoxic agents in the comet assay.
Montag G; Bankoglu EE; Bolte A; Hintzsche H; Djelic N; Stopper H
Mutat Res Genet Toxicol Environ Mutagen; 2019 Sep; 845():402972. PubMed ID: 31561892
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Bandele OJ; Osheroff N
Biochemistry; 2008 Nov; 47(45):11900-8. PubMed ID: 18922022
[TBL] [Abstract][Full Text] [Related]
36. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
Benchokroun Y; Couprie J; Larsen AK
Biochem Pharmacol; 1995 Jan; 49(3):305-13. PubMed ID: 7857317
[TBL] [Abstract][Full Text] [Related]
37. Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells.
Aratani Y; Andoh T; Koyama H
Mutat Res; 1996 Feb; 362(2):181-91. PubMed ID: 8596537
[TBL] [Abstract][Full Text] [Related]
38. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
Bojanowski K; Lelievre S; Markovits J; Couprie J; Jacquemin-Sablon A; Larsen AK
Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3025-9. PubMed ID: 1313577
[TBL] [Abstract][Full Text] [Related]
39. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Holm B; Sehested M; Jensen PB
Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
[TBL] [Abstract][Full Text] [Related]
40. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents.
van Hille B; Hill BT
Cancer Chemother Pharmacol; 1998; 42(5):345-56. PubMed ID: 9771947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
